参考文献/References:
[1] 张志伟.异丙托溴铵与孟鲁司特纳联合治疗毛细支气管炎患儿临床疗效观察[J].标记免疫分析与临床,2017,24(10):1180-1182,1192.
[2] 穆艳顺,刘 萍,刘花玲,等.喜炎平雾化联合孟鲁司特钠治疗小儿毛细支气管炎的临床观察[J].中国医药导报,2013,10(34):80-81,85.
[3] Kim SB,Lee JH,Lee J,et al.The efficacy and safety of Montelukast sodium in the prevention of bronchopulmonary dysplasia[J].Korean J Pediatr,2015,58(9):347-353.
[4] 雷玉琳.氨溴特罗口服溶液联合孟鲁司特钠咀嚼片治疗儿童急性支气管炎的临床效果[J].中国医药导报,2017,14(6):124-127.
[5] 周长华.喘息性支气管炎稳定期患儿口服孟鲁司特钠预防喘息及哮喘发作的随访评价[J].河北医药,2015,37(9):1348-1350.
[6] Ibrahim FA,El-Enany N,El-Shaheny RN,et al.Simultaneous determination of desloratadine and montelukast sodium using second-derivative synchronous fluorescence spectrometry enhanced by an organized medium with applications to tablets and human plasma[J].Luminescence,2015,30(4):485-494.
[7] Kim DW,Kim YH,Yousaf AM,et al.Novel montelukast sodium-loaded stable oral suspension bioequivalent to the commercial granules in rats[J].Arch Pharm Res,2016,39(4):539-546.
[8] 郑海丽,王清兰.甲基强的松龙联合孟鲁司特钠治疗毛细支气管炎的疗效观察[J].天津医药,2013,41(3):263-264.
[9] 邱锐琴,乔 木,苏 颖.孟鲁司特钠对毛细支气管炎患儿血嗜酸性粒细胞趋化因子和干扰素γ的影响及其意义[J].河北医科大学学报,2014,35(2):156-159.
[10] Takahashi M,Taniuchi S,Soejima K,et al.New efficacy of LTRAs(montelukast sodium):it possibly prevents food-induced abdominal symptoms during oral immunotherapy[J].Allergy Asthma Clin Immunol,2014,10(1):3.
[11] Hafeez S,Islam A,Gull N,et al.gamma-Irradiated chitosan based injectable hydrogels for controlled release of drug(Montelukast sodium)[J].Int J Biol Macromol,2018,114:890-897.
[12] 刘宗文.孟鲁司特钠防治喘息性支气管炎的临床观察[J].北京医学,2016,38(7):647,653.
[13] 周瑞琴,陈 强.孟鲁司特钠口服预防呼吸道合胞病毒毛细支气管炎后反复喘息及哮喘的研究[J].现代中西医结合杂志,2015,24(20):2235-2237.